Skip to main content

Table 2 Relationship between clinical outcome and multi-locus genotypes

From: Relationship between Trypanosoma brucei rhodesiense genetic diversity and clinical spectrum among sleeping sickness patients in Uganda

Characteristic Frequency Associated MLGs
Severity of neurological response
 Mild (13–15) 19 (82.6%) 1,2,3,4,5,6,7,8,9,10,12,13,14,15,16,17
 Moderate (9–12) 3 11,13,14
 Severe (≤ 8) 1 4
Disease duration (months)
 < 1 14 (63.6%) 4,5,9,12,13,14,16,17
 1–3 7 1,2,3,6,8,10,11
 > 3 1 4
Clinical presentation
 Fever
  Yes 24 (100%) 1,2,3,4,5,6,7,8,9,10,11,12,13,14,16,17
  No 0  
 Headache
  Yes 22 (91.7%) 1,2,3,4,5,7,8,9,10,11,12,13,14,15
  No 2 9,17
 Hepatomegaly
  Yes 2 (8.3%) 4,5
  No 22 1,2,3,4,6,7,8,9,10,11,12,13,14,15,16,17
 Lymphadenopathy
  Yes 8 (33.3%) 2,4,9,10,13,14,15
  No 16 1,3,4,5,6,7,8,9,11,12,13,14,15,16,17
 Splenomegaly
  Yes 6 (25%) 4,5,9,13,14,16
  No 18 1,2,3,4,6,7,8,9,10,11,12,13,14,15,17
 Edema
  Yes 4 (16.7%) 4,13,16
  No 20 1,2,3,4,5,5,6,7,8,9,10,11,12,13,14,15,17
 Somnolence
  Yes 9 (37.5%) 1,2,3,5,6,8,9,10,12
  No 15 2,4,7,11,13,14,15,16,17
 Gait abnormalities
  Yes 6 (25%) 1,4,13,9,11
  No 18 2,3,4,5,6,7,8,9,10,12,13,14,15,16,17
 Tremors
  Yes 2 (8.3%) 11,15
  No 22 1,2,3,4,5,6,7,8,9,10,12,13,14,15,16,17
 Urinary incontinence
  Yes 2 (8.3%) 4,11
  No 22 1,2,3,4,5,6,7,8,9,10, 12,13,14,15,16,17
 Cranioneuropathy
  Yes 3 (15%) 14,15
  No 20 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16
  1. Multi-locus genotypes indicated in italics were present in those with and without the clinical sign or across groups